The work could help guide drug discovery and development by revealing how disease disrupts cells.

Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.

Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the co-lead programs target hepatocellular carcinoma and colorectal cancer) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.

Andrew Lam describes his career journey that started with a Doctor of Pharmacy education before working in industry, the investment world, back in industry, and then settling at Ally Bridge. He discusses the successful investments Ally Bridge has made in biotech, including in technologies like radiopharmaceuticals and ADCs, and the concept of being a bridge to China innovation. Chapters Intro and early life - 1:37 Initial industry roles - 10:27 Investment industry - 13:38 BD

Interviewed by Sisterhood Editorial Board Member Erika Smith, Rachel King reflects on her time at NEA and 18 years as the Co-Founder & CEO at GlycoMimetics, as well as stepping into the role of BIO's CEO on an interim basis. She offers leadership advice, and describes the ways she still says active in biotech today. Biographies Rachel King was CEO of the Biotechnology Innovation Organization and co-founder and CEO of GlycoMimetics, a publically traded biotechnology company. B

CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16.

He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA. Chapters The economic impact of biotech - 1:28 Global competition

CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner.

CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Oroxo also has plans for a nasal spray GLP and vaccines.

CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.

CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.

Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.

CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.

Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.

Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome. Chapters Intros - 1:11 Ilan Ganot | Starting a DMD company - 6:17 Daniel Fischer | Starting a Dravet company - 8:39 The Massachusetts ecosystem - 10:36 Being a CEO - 18:48 Advice for other parents - 23:43 Incentivizi

MassBio CEO Kendalle Burlin O'Connell highlights key findings of the report, including that employment in life sciences was down in 2025 for the first time in decades, and suggests that we should be both optimistic about the current state of the sector but mindful to make seed investments to keep it up over the longer term. Download the Report

BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from Japan and building companies around them internationally., and also in-licensing assets approved elsewhere and doing the clinical work in Japan to get them approved there. Plus, the story of the GHIT Fund, which is meant to bring Japanese innovation to neglected disease